2011

1 Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy. W Bannister, A Cozzi-Lepri, J Kjær, B Clotet, A Lazzarin, JP Viard, G Kronborg, D Duiculescu, M Beniowski, L Machala, A Phillips;

J Antimicrob Chemother.2011 Apr;66(4):901-11. Epub 2011 Jan 31. article

2 Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*).K Petoumenos, S Worm, P Reiss, S de Wit, A d'Arminio Monforte, C Sabin, N Friis-Møller, R Weber, P Mercie, C Pradier, W El-Sadr, O Kirk, JD Lundgren, M Law; for the D:A:D study group.
HIV Med. 2011 Aug;12(7):412-21. doi: 10.1111/j.1468-1293.2010.00901.x. Epub 2011 Jan 20. article

3 Risk factors for fatality in HIV-infected patients with dideoxynucleoside-induced severe hyperlactataemia or lactic acidosis. A Arenas-Pinto, A Grant, K Bhaskaran, A Copas, A Carr, SW Worm, E Martinez, P Reiss, D Dunn, R Weber, J Hoy, I Weller, the Lactic Acidosis International study group.
Antivir Ther. 2011;16(2):219-26. abstract

4 Factors associated with the development of cytomegalovirus infection following solid organ transplantation. C da Cunha-Bang, SS Sørensen, M Iversen, VH Sengel, JG Hillings, A Rasmussen, SA Mortensen, ZV Fox, NS Kirkby, CB Christiansen, JD Lundgren.
Scand J Infect Dis. 2011 May;43(5):360-5. Epub 2011 Feb 9]. article

5 Regarding: humar et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. C da Cunha-Bang, M Iversen, SA Mortensen, A Rasmussen, H Sengeløv, SS Sørensen, J Lundgren.
Am J Transplant. 2011 Feb;11(2):408. doi: 10.1111/j.1600-6143.2010.03349.x. Epub 2011 Jan 10. article

6 A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: Results from the EuroSIDA study. JD Kowalska, A Mocroft, B Ledergerber, E Florence, M Ristola, J Begovac, H Sambatakou, C Pedersen, JD Lundgren, O Kirk, for the EuroSIDA study group.
HIV Clin Trials. 2011 Mar-Apr;12(2):109-17. abstract

7 Acute hepatitis C in HIV-infected individuals- recommendations from the NEAT consensus conference. JK Rockstroh; The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel.
AIDS. 2011 Feb 20;25(4):399-409. abstract

8 Risk of triple-class virological failure in children with HIV: a retrospective cohort study.Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), H Castro, A Judd, DM Gibb, K Butler, RK Lodwick, A van Sighem, JT Ramos, J Warsawski, C Thorne, A Noguera-Julian, N Obel, D Costagliola, PA Tookey, C Colin, J Kjaer, J Grarup, G Chene, A Phillips.
Lancet. 2011 May 7;377(9777):1580-7. Epub 2011 Apr 20. article

9 HIV in hiding: methods and data requirements for the estimation of the number of people living with undiagnosed HIV. Working Group on Estimation of HIV Prevalence in Europe.
AIDS. 2011 May 15;25(8):1017-23. abstract

10 Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy - a European multi-cohort study. The EuroCoord-CHAIN joint project. L Wittkop, HF Günthard, F de Wolf, D Dunn, A Cozzi-Lepri, A de Luca, C Kucherer, N Obel, V von Wyl, B Masquelier, C Stephan, C Torti, A Antinori, F Garcia, A Judd, K Porter, R Thiébaut, H Castro, AI van Sighem, C Colin, J Kjær, JD Lundgren, R Paredes, A Pozniak, B Clotet, A Phillips, D Pillay, G Chêne.
Lancet Infectious Diseases. 2011 May;11(5):363-371. Epub 2011 Feb 25. article

11 A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practise across Europe : A EuroSIDA study.J Reekie, P Reiss, B Ledergerber, D Sedlacek, M Parczewski, J Gatell, C Katlama, G Fatkenhaeur, JD Lundgren, A Mocroft.
HIV Med. 2011 May;12(5):259-68. doi: 10.1111/j.1468-1293.2010.00877.x. Epub 2010 Aug 31. article

12 The Coding Causes of Death in HIV (CoDe) Project- Initial results and evaluation of methodology. JD Kowalska, N Friis-Møller, O Kirk, W Bannister, A Mocroft, C Sabin, P Reiss, J Gill, C Lewden, A Phillips, A d'Arminio Monforte, M Law, J Sterne, S De Wit, JD Lundgren, the CoDe working group and the D:A:D study group.
Epidemiology. 2011 Jul;22(4):516-523. [Epub ahead of print]. abstract

13 Tuberculosis among HIV-postive patients across Europe: changes over time and risk factors. A Kruk, W Bannister, D Podlekareva, N Chentsova, A Rakhmanova, A Horban, P Domingo, A Mocroft, J Lundgren, O Kirk; on behalf of the EuroSIDA study group.
AIDS. 2011 JUl 31;25(12):1505-13. Epub ahead of print 2011 May 21 . abstract

14 Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. JP Viard, JC Souberbielle, O Kirk, J Reekie, B Knysz, M Losso, J Gatell, C Pedersen, JR Bogner, JD Lundgren, A Mocroft for the EuroSIDA Study Group.
AIDS. 2011 Jun 19;25(10):1305-1315. abstract

15 The metabolic syndrome in HIV. SW Worm, JD Lundgren.
Best Pract Res Clin Endocrinol Metab. 2011 Jun;25(3):479-86. doi: 10.1016/j.beem.2010.10.018. article

16 Elevated triglycerides and risk of MI in HIV-positive persons, the D:A:D study. SW Worm, DA Kamara, P Reiss, O Kirk, W El-Sadr, C Fux, E Fontas, A Phillips, AD Monforte, S De Wit, K Petoumenos, N Friis-Møller, P Mercie, J Lundgren, C Sabin.
AIDS. 2011 Jul 31;25(12):1497-504. article

17 Antibiotics in intensive care: too little or too much? ME Johansen, JU Jensen, JD Lundgren.
Crit Care Med. 2011 Jul;39(7):1849-51. abstract

18 Mortality in enterococcal bloodstream infections increases with inappropriate antimicrobialtherapy. M Suppli, R Aabenhus, ZB Harboe, LP Andersen, M Tvede, JU Jensen. Clin Microbiol Infect. 2011 Jul;17(7):1078-83. doi:10.1111/j.1469-0691.2010.03394.x. Epub 2010 Dec 3. article

19 The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: The D:A:D Study. DA Kamara, SW Worm, P Reiss, M Rickenbach, A Phillips, O Kirk, AD Monforte, M Bruyand, M Law, S De Wit, C Smith, C Pradier, JD Lundgren, C Sabin.
J Infect Dis. 2011 Aug;204(4):521-525. article

20 Procalcitonin-guided interventions against infections to increase early appropriate antibiotics and improve survival in the intensive care unit: a randomized trial. JU Jensen, L Hein, B Lundgren, MH Bestle, TT Mohr, MH Andersen, KJ Thornberg, J Løken, M Steensen, Z Fox, H Tousi, P Søe-Jensen, AØ Lauritsen, D Strange, PL Petersen, N Reiter, S Hestad, K Thormar, P Fjeldborg, KM Larsen, NE Drenck, C Ostergaard, J Kjær, J Grarup, JD Lundgren; Procalcitonin And Survival Study (PASS) Group.
Crit Care Med. 2011 Sep;39(9):2048-58. abstract

21 HIV infection, aging and cardiovascular disease: epidemiology and prevention. K Petoumenos, SW Worm.
Sex Health. 2011 Nov;8(4):465-73. article

22 Predictors of having a resistance test following confirmed virological failure of cART: data from EuroSIDA. ZV Fox, A Cozzi-Lepri, A d'Arminio Monforte, A Karlsson, AN Phillips, G Kronborg, J Kjaer, B Clotet, JD Lundgren for EuroSIDA.
Antivir. Ther. 2011;16(5):781-5. abstract

23 Hepatitis delta in HIV-infected individuals in Europe. V Soriano, D Grint, A d'Arminio Monforte, A Horban, C Leen, E Poveda, F Antunes, S De Wit, J Lundgren, J Rockstroh, L Peters.
AIDS. 2011 Oct 23;25(16):1987-92.article

24 Fatal and non-fatal AIDS and non-AIDS events in HIV-1 positive individuals with high CD4 counts according to viral load strata. J Reekie, J Gatell, I Yust, E Bakowska, A Rakhmanova, M Losso, M Krasnov, P Francioli, J Kowalska, A Mocroft; EuroSIDA in EuroCoord.
AIDS. 2011 Nov 28;25(18):2259-68. abstract

25 Factors associated with HIV-1 virological failure in an outpatient clinic for HIV-infected people in Haiphong, Vietnam. DT Huong, W Bannister, PT Phong, O Kirk, L Peters.
Int J STD AIDS. 2011 Nov;22(11):659-64. article

26 Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. SMART Study Group, L Peters, J Neuhaus, A Mocroft, V Soriano, J Rockstroh, G Dore, M Puoti, E Tedaldi, B Clotet, B Kupfer, JD Lundgren, MD Klein.
Antivir Ther. 2011;16(5):667-75. article

27 Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet? R Aabenhus, JU Jensen.
Prim Care Respir J. 2011 Dec;20(4):360-7. article

28 A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy. R Paredes, MC Puertas, W Bannister, M Kisic, A Cozzi-Lepri, C Pou, R Bellido, G Betancor, J Bogner, P Gargalianos, D Bánhegyi, B Clotet, J Lundgren, L Menéndez-Arias, J Martinez-Picado; The EuroSIDA Study Group.
J Infect Dis. 2011 Sep 1;204(5):741-52. article

29 Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. EZ Soliman, JD Lundgren, MP Roediger, DA Duprez, Z Temesgen, M Bickel, JC Shlay, C Somboonwit, P Reiss, JH Stein, JD Neaton, INSIGHT SMART Study Group.
AIDS. 2011 Jan 28;25(3):367-77. article

30 Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. A Cozzi-Lepri, MCF Prosperi, J Kjær, D Dunn, R Paredes, CA Sabin, JD Lundgren, AN Phillips, D Pillay, for the EuroSIDA and the United Kingdom CHIC/United Kingdom HDRD Studies.
PLoS One. 2011;6(11):e25665. Epub 2011 Nov 16. article

31 Cardiovascular implications from untreated human immunodeficiency virus infection. JV Baker, JD Lundgren.
Eur Heart J. 2011 Apr;32(8):945-51. Epub 2011 Jan 12. article

32 Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. JV Baker, J Neuhaus, D Duprez, LH Kuller, R Tracy, WH Belloso, S De Wit, F Drummond, HC Lane, B Ledergerber, J Lundgren, DE Nixon, NI Paton, JD Neaton, INSIGHT SMART Study Group.
J Acquir Immune Defic Syndr. 2011 Jan;56(1):36-43.article

33 Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AN Phillips, D Pillay, G Garnett, D Bennett, M Vitoria, V Cambiano, J Lundgren.
AIDS. 2011 Mar 27;25(6):843-50. article

34 Haemoglobin and anaemia in the SMART study. A Mocroft, AR Lifson, G Touloumi, J Neuhaus, Z Fox, A Palfreeman, MJ Vjecha, S Hodder, S De Wit, JD Lundgren, AN Phillips, INSIGHT SMART Study Group.
Antivir Ther. 2011;16(3):329-37. article

35 Prevention of HIV-1 infection with antiretroviral therapy. A Rodger, A Phillips, J Lundgren.
N Engl J Med. 2011 Nov 17;365(20):1934; author reply 1935. article

36 Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. EZ Soliman, RJ Prineas, MP Roediger, DA Duprez, F Boccara, C Boesecke, C Stephan, S Hodder, JH Stein, JD Lundgren, JD Neaton.
J Electrocardiol. 2011 Nov-Dec;44(6):779-85. Epub 2010 Dec 8. article

37 The Global Fund’s resource allocation decisions for HIV programmes: addressing those in need. O Avdeeva, JV Lazarus, MA Aziz, R Atun.
J Int AIDS Soc. 2011 Oct 26;14:51. article

38 Critical Interactions between the Global Fund-Supported HIV Programs and the Health System in Ghana. R Atun, SK Pothapregada, J Kwansah, D Degbotse, JV Lazarus.
J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 2:S72-6. article

39 Attitude of Lithuanian Residents to Confidentiality of Adolescent Sexual and Reproductive health Care. L Jaruseviciene, JV Lazarus, A Zaborskis.
Central European J Public Health, 2011; 19(4): 211-217. abstract

40 Overcoming obstacles to late presentation for HIV infection in Europe. JV Lazarus, R Jürgens, M Weait, A Phillips, J Hows, J Gatell, T Coenen, A Sönnerborg, D Raben and JD Lundgren.
HIV Med. 2011 Apr;12(4):264-9. article

41 A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice across Europe: a EuroSIDA study. J Reekie, P Reiss, B Ledergerber, D Sedlack, M Parczewski, J Gatell, C Katlama, G Fätkenheuer, JD Lundgren, A Mocroft; for the EuroSIDA Study Group.
HIV Med. 2011 May;12(5):259-68. abstract

42 Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy - a European multi-cohort study. The EuroCoord-CHAIN joint project. L Wittkop, HF Günthard, F de Wolf, D Dunn, A Cozzi-Lepri, A de Luca, C Kucherer, N Obel, V von Wyl, B Masquelier, C Stephan, C Torti, A Antinori, F Garcia, A Judd, K Porter, R Thiébaut, H Castro (née Green), AI van Sighem, C Colin, J Kjær, JD Lundgren, R Paredes, A Pozniak, B Clotet, A Phillips, D Pillay, G Chêne.
Lancet Infectious Diseases. 2011 May;11(5):363-371. Epub 2011 Feb 25. abstract

43 Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.JD Kowalska, J Reekie, A Mocroft, P Reiss, B Ledergerber, J Gatell, AD Monforte, A Phillips, JD Lundgren, O Kirk; for the EuroSIDA study group.
AIDS. 2011 Nov 22. [Epub ahead of print] article 

44 Disseminated mycobacterium abscessus infection in an AIDS patient. JR Lambertucci, AHD Borges, I Voieta. 
Sociedade Brasileira de Medicina Tropical. 2011 Mar-Apr;44(2):265. (IF:0.942) abstract

2010

1 Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. V Soriano, A Mocroft, L Peters, J Rockstroh, F Antunes, N Kirkby, S de Wit, A d'Arminio Monforte, Robert Flisiak and J Lundgren on behalf of EuroSIDA
J Antimocrob Chemother. 2010 Mar;65(3):548-55. article

2 History of viral suppression on cART as a predictor of virological failure after a treatment change. J Reekie, A Mocroft, B Ledergerber, M Beniowski, B Clotet, J van Lunzen, A Chiesi, C Pradier, L Machala, J D Lundgren on behalf of the EuroSIDA Study Group.
HIV Medicine. 2010 Aug;11(7):469-78. Epub 2010 Feb 22.article

3 Markers of inflammation, coagulation and renal function are elevated in adults with HIV infection. J Neuhaus, DR Jacobs Jr., JV Baker, A Calmy, D Duprez, A La Rosa, LH Kuller, SL Pett, M Ristola, MJ Ross, MG Shlipak, R Tracy, JD Neaton for the INSIGHT SMART, MESA and CARDIA Research Groups
J Infect Dis 2010; 201(12):1788-1795. article

4 Risk of all-cause mortality associated with non-fatal AIDS and serious non-AIDS events among adults infected with HIV. J Neuhaus, B Angus, J Kowalska, A La Rosa, J Sampson, D Wentworth, A Mocroft; for the INSIGHT SMART and ESPRIT Study Groups.
AIDS. 2010 March 1324(5):697-706. article

5 Relationship between current level of immunodeficiency and non-AIDS defining malignancies. J Reekie, C Kosa, F Engsig, A d'Arminio Monforte, A Wiercinska-Drapalo, P Domingo, F Antunes, N Clumeck, O Kirk, JD Lundgren, A Mocroft for the EuroSIDA study group.
Cancer. 2010 Nov15;116(22):5306-15. article

6 Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years.The Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
Arch Intern Med 2010, 170:410-419. article

7 Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. A Mocroft, O Kirk, P Reiss, S De Wit, D Sedlacek, M Beniowski, J Gatell, AN Phillips, B Ledergerber, JD Lundgren, for the EuroSIDA Study Group.
AIDS. 2010 Jul 17;24(11):1667-78. article

8 Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: Collaborative analysis of 13 HIV cohort studies. The Antiretroviral Therapy Cohort Collaboration Study Group (ART-CC).
Clin Infect Dis. 2010 May 15;50(10):1387-96. article

9 High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. SW Worm, N Friis-Møller, M Bruyand, A D'Arminio Monforte, M Rickenbach, P Reiss, W El-Sadr, A Phillips, J Lundgren, C Sabin, for the DAD study group.
AIDS. 2010 Jan 28;24(3):427-35. article

10 Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study. Worm SW, Sabin S, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Fontas E, Weller I, Phillips a, Lundgren J.
J Infect Dis. 2010 Feb 1;201(3):318-30. article

11 Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HV infection and a CD4 cell count <200 cells/mL? The Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE).
Clinical Infectious Diseases. 2010;51(5):611-19. article

12 Estimated average annual rate of change of CD4 counts in patients on combination antiretroviral therapy. A Mocroft, AN Phillips, B Ledergerber, C Smith, JR Bogner, K Lacombe, A Wiercinska-Drapalo, P Reiss, O Kirk, JD Lundgren for the EuroSIDA study group.
Antiviral Therapy 2010. 15:563-570.abstract 

13 Predicting the risk of cardiovascular disease in HIV-infected patients: the Data Collection on Adverse Effects of Anti-HIV Drugs Study. N Friis-Møller, R Thiébaut, P Reiss, R Weber, AD Monforte, S De Wit, W El-Sadr, E Fontas, S Worm, O Kirk, A Phillips, C Sabin, JD Lundgren, M Law; for the DAD study group.
Eur J Cardiovasc Prev Rehabil. 2010 Oct;17(5):491-501. abstract

14 Overcoming obstacles to late presentation for HIV infection in Europe. JV Lazarus, R Jürgens, M Weait, A Phillips, J Hows, J Gatell, T Coenen, A Sönnerborg, D Raben and JD Lundgren.
HIV Medicine. 2010 Aug 29. abstract 

15 Notification of suspected and unexpected serious adverse reactions according to the Clinical Trials Directive - A descriptive analysis of the legislation and the requirements in a European context. EM Larsen, J Grarup, DC Gey, KB Jensen, O Kirk.
Clinical Research and Regulatory Affairs Dec 2010, Vol. 27, No. 4:108–120 article

16 Dialysis and Renal Transplantation in HIV-Infected Patients: a European Survey. JC Trullas, A Mocroft, F Cofan, J Tourret, A Moreno, CI Bagnis, CA Fux, C Katlama, P Reiss, J Lundgren, JM Gatell, O Kirk, JM Miró; the EuroSIDA Investigators.
J Acquir Immune Defic Syndr. 2010 Aug 31. [Epub ahead of print]abstract

17 Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. GJ Dore, V Soriano, J Rockstroh, B Kupfer, E Tedaldi, L Peters, J Neuhaus, M Puoti, MB Klein, A Mocroft, B Clotet, JD Lundgren for the SMART INSIGHT study group.
AIDS 2010; 24:857-865. abstract

18 Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy. FC Lampe, DA Duprez, LH Kuller, R Tracy, J Otvos, E Stroes, DA Cooper, J Hoy, NI Paton, N Friis-Moller, J Neuhaus, AP Liappis, AN Phillips for the INSIGHT SMART Study Group.
J Acquir Immun Defic Synd 2010; 54(3):275-284. abstract

19 Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. Achhra A, Amin J, Law MG, Emery S, Gerstoft J, Gordin FM, Vjecha MJ, Neaton JD, Cooper DA for INSIGHT ESPRIT & SILCAAT study groups.
AIDS 2010; 24(12):1877-1886. abstract

20 Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study. Tavel JA, INSIGHT STALWART Study Group.
PLoS One 2010; 5(2): e9334. doi:10.1371/journal.pone.0009334. abstract

21 Smoking-related risk of all-cause mortality and serious clinical events among HIV-infected patients receiving highly active antiretroviral therapy in the Strategies for Management of Antiretroviral Therapy clinical trial. Lifson AR, Neuhaus J, Arribas JR, van den Bergwolf M, Labriola MN, Read TRH for the INSIGHT SMART study group.
Am J Pub Health 2010; Aug 19, 2010, epub ahead of print. abstract

22 The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters. Martinez E, Visnegarwala F, Grund B, Thomas A, Gibert C, Shlay J, Drummond F, Pearce D, Edwards S, Reiss P, El-Sadr W, Carr A for the INSIGHT SMART study group.
AIDS 2010; 24:353-363.abstract

23 Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D study. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study group. C Smith, SW Worm, N Friis-Møller, CA Sabin, A Sjøl, JD Lundrgen, R Salbøl-Brandt, M Rickenbach, P Pezzotti, E Krum, L Gras, E Balestre, A Sundström, M Delforge, E Fontas, F Torres, K Petoumenos, J Kjær, S Collins, S Storpher, G Pearce, R Rode, I Weller.
AIDS. 2010 Jun 19;24(10):1537-48.abstract

24 HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. R Weber, C Sabin, P Reiss, S de Wit, SW Worm, M Law, F Dabis, A d'Arminio Monforte, E Fontas, W El-Sadr, O Kirk, M Rickenbach, A Phillips, B Ledergerber, J Lundgren.
Antivir Ther. 2010;15(8):1077-86. abstract

25 Rescue of severely immunocompromised HIV-positive persons. JD Lundgren, AN Phillips.
J Infect Dis. 2010 Nov 15;202(10):1467-9. [Editorial Commentary on: J Infect Dis. 2010 Nov 15;202(10):1529-37.] abstract

26 Biomarkers in HIV Disease. JD Lundgren, J Baxter, SG Deeks, HC Lane.
Curr Opin HIV & AIDS. 2010 Nov;5(6):459-62. abstract

27 Role of biomarkers in predicting CVD risk in the setting of HIV infection? SW Worm, P Hsue.
Curr Opin HIV & AIDS. 2010 Nov;5 (6):467-72. abstract

28 Biomarkers of fibrosis and impaired liver function in chronic hepatitis C: how well do they predict clinical outcomes? L Peters, JK Rockstroh. Curr Opin HIV & AIDS. 2010 Nov;5(6):517-23.abstract

29 Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. JD Neaton, A Babiker, M Bohnhorst, J Darbyshire, E Denning, A Frishman, J Grarup, G Larson, J Lundgren. Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.
Clin Trials. 2010 Dec;7(6):705-18. abstract

30 Use of biomarker procalcitonin for diagnosis, prognosis, and treatment guidance in critically ill patients. ME Johansen, JU Jensen.
Klinisk Biokemi i Norden. 2010;4(22). abstract

31 A comparison of the long term durability of nevirapine, efavirenz and lopinavir in routine clinical practise across Europe: a EuroSIDA study. J Reekie, P Reiss, B Ledergerber, D Sedlacek, M Parczewski, J Gatell, C Katlama, G Fätkenheuer, JD Lundgren, A Mocroft; for the EuroSIDA study group.
HIV Med. 2010 Aug 31. [Epub ahead of print] abstract

32 Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection.JV Baker, J Neuhaus, D Duprez, LH Kuller, R Tracy, WH Belloso, S De Wit, F Drummond, HC Lane, B Ledergerber, J Lundgren, DE Nixon, NI Paton, JD Neaton for the INSIGHT SMART study group.
J Acquir Immun Defic Synd 2010. abstract

33 Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. A Mocroft, P Reiss, J Gasiorowski, B Ledergerber, J Kowalska, A Chiesi, J Gatell, A Rakhmanova, M Johnson, O Kirk, J Lundgren; EuroSIDA Study Group. 
J Acquir Immune Defic Syndr. 2010 Oct;55(2):262-70.

2009

1 Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in EuroSIDA. M van Luin, WP Bannister, A Mocroft, P Reiss, G Di Perri, G Peytavin, J Molto, A Karlsson, A Castagna, M Beniowski, JD Lundgren, DM Burger; the EuroSIDA study group
Antiviral Therapy. 2009;14(1):75-83. PMID: 19320239. abstract

2 Use of risk equations for predicting disease progression in HIV infection. A Mocroft, JD Lundgren.
Clin Infect Dis. abstract

3 Procalcitonin monitoring in trauma intensive care patients: how helpful is it? JU Jensen, JD Lundgren.
Critical Care Medicine 2009 Jun;37(6):2093-4. PubMed PMID: 19448450. abstract

4 Hepatitis C Virus (HCV) Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1 Infected Patients with Maximum Virologic Suppression. L Peters, A Mocroft, V Soriano, J Rockstroh, P Aldins, M Losso, L Valerio, P Reiss, B Ledergerber, J Lundgren, for the EuroSIDA Study Group.
JAIDS. 2009 April;50(5):457-463. abstract

5 Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. When to Start Consortium, J A Sterne, M May, D Costagliola, F De Wolf, A N Phillips, R Harris, M J Funk, R Geskus, J Gill, F Dabis, J M Miró, A Justice, B Ledergerber, G Fätkenheuer, R Hogg, A D'Arminio Monforte, M Saag, C Smith, S Staszewski, M Egger, S R Cole.
Lancet. 2009 Apr 18;373(9672):1352-63.Epub 2009 Apr 8. review. abstract

6 Major breakthroughs in the medical treatment of HIV infection.O Kirk, J Gerstoft, JD Lundgren, N Obel.
Ugeskr Laeger. 2009 Mar 2;171(10):787-789.full article

7 Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the DATA Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). SW Worm, S De Wit, R Weber, CA Sabin, P Reiss, W El-Sadr, AD Monforte, O Kirk, E Fontas, F Dabis, MG Law, JD Lundgren, N Friis-Møller.
Circulation. 2009 Feb 17;119(6):805-11. Epub 2009 Feb 2. abstract

8 Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D study). SW Worm, CA Sabin, P Reiss, W El-Sadr, A Monforte, C Pradier, R Thiebaut, M Law, M Richenbach, S De Wit, JD Lundgren, N Friis-Møller.
Diabetes Care. 2009 Mar;32(3):474-80. Epub 2008 Dec 3. abstract

9 Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy. A M Kesselring, F W Wit, C A Sabin, J D Lundgren, J Gill, J Gatell, A Rauch, J S Montaner, F de Wolf, P Reiss, A Mocroft.
AIDS. 2009 Aug 24;23(13):1689-99. abstract

10 The ART Cohort Collaboration: Variable impact on mortality of AIDS defining events diagnosed during combination antiretroviral therapy: Not all AIDS Defining Conditions are Created Equal. Writing committee: Mocroft, A., Sterne, J., Egger, M., May, M., Grabar, S., Furrer, H., Sabin, C., Fatkenheuer, G., Justice, A., Reiss, P., d’Arminio Monforte, A., Gill, J., Hogg, R., Bonnet, F., Kitahata, M., Staszewski, S., Casabona, J., Harris, R. and Saag, M.
Clin Infect Dis. 2009 Apr 15;48(8):1138-51. PubMed PMID: 19275498. abstract

11 Activation and Coagulation Biomarkers are Independent Predictors of the Development of Opportunistic Disease in Patients with HIV Infection. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; the INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.
J Infect Dis. 2009 Sep 15;200(6):973-983. PubMed PMID:19678756. abstract

12 Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to
Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resource-Limited Settings. Cozzi-Lepri A, Phillips AN, Martinez-Picado J, d'Arminio Monforte A, Katlama C, Hansen AB, Horban A, Bruun J, Clotet B, Lundgren JD; EuroSIDA Study Group.
J Infect Dis. 2009 Sep 1;200(5):687-697. PubMed PMID: 19604043. abstract

13 Cost-effectiveness of strategies for monitoring the response to antiretroviral therapy in resource-limited settings. Phillips AN, Gilks C, Lundgren JD.
Arch Intern Med. 2009 May 11;169(9):904; author reply 904-5. PubMed PMID:19433706. abstract

14 Risk of virus transmission from well-treated patients with HIV? Gerstoft J, Mathiesen L, Lundgren JD, Nielsen HI, Pedersen C, Obel N, Laursen A.
Ugeskr Laeger. 2009 Mar 23;171(13):1085. Danish. PubMed PMID: 19321080. abstract

15 Uncertainty as to whether the use of antiretroviral therapy for persons recently infected with HIV has a favorable risk-to-benefit ratio. Lundgren JD, Phillips AN, Neaton J.
Clin Infect Dis. 2009 Apr 15;48(8):1162; author reply 1162-3. PubMed PMID: 19292638. abstract

16 Interruption of antiretroviral therapy is associated with increased plasma cystatin C. Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.
AIDS. 2009 Jan 2;23(1):71-82. PubMed PMID: 19050388. abstract

17 Relative risk of death in the SMART study. B Grund, J Neuhaus, A Phillips; INSIGHT SMART Study Group.
Lancet Infect Dis. 2009 Dec;9(12):724-5.

18 Lipoprotein particle subclasses, cardiovascular disease and HIV infection. DA Duprez, LH Kuller, R Tracy, J Otvos, DA Cooper, J Hoy, J Neuhaus, NI Paton, N Friis-Møller, F Lampe, AP Liappis, JD Neaton for the INSIGHT SMART Study Group.
Atherosclerosis 2009; doi:10.1016/j.atherosclerosis.2009.05.001 (epub first). abstract

19 Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group.
AIDS. 2009 Sep 24;23(15):2029-37. abstract

20 Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. Podlekareva DN, Mocroft A, Post FA, Riekstina V, Miro JM, Furrer H, Bruyand M, Panteleev AM, Rakhmanova AG, Girardi E, Losso MH, Toibaro JJ, Caylá J, Miller RF, Obel N, Skrahina A, Chentsova N, Lundgren JD, Kirk O; HIV/TB Study Writing Group.
AIDS. 2009 Nov 27;23(18):2485-95. abstract

21 Interleukin-2 therapy in patients with HIV infection. INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D.
N Engl J Med. 2009 Oct 15;361(16):1548-59. abstract

22 Incidence and risk factors of HIV-related non-Hodgkin lymphoma in the era of combination antiretroviral therapy: European multi-cohort study.The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group.
Antiviral Ther. 2009; 14(8):1065-74 abstract

23 Implementing the number needed to harm in clinical practice: risk of myocardial infarction in HIV-1-infected patients treated with abacavir. JD Kowalska, O Kirk, A Mocroft, L Høj, N Friis-Møller, P Reiss, I Weller, JD Lundgren.
HIV Medicine. Early View, October 2009. abstract

24 Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Antiretroviral Therapy Cohort Collaboration.
Int J Epidemiol. 2009 Dec;38(6):1624-33. abstract

25 Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. Antiretroviral therapy cohort collaboration (ART-CC), Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte AD, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne JA, Costagliola D.
AIDS. 2009 Oct 23;23(16):2199-208. abstract

26 Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression. Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JA; Antiretroviral Therapy Cohort Collaboration.
J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):357-63. abstract

27 Continuous antiretroviral therapy decreases bone mineral density. Grund B, Peng G, Gibert CL, Hoy JF, Isaksson RL, Shlay JC, Martinez E, Reiss P, Visnegarwala F, Carr AD for the INSIGHT SMART body composition substudy group.
AIDS 2009; 23:1519-1529. abstract

28 Benefits and burdens of participation in a longitudinal clinical trial. Lazovski J, Losso M, Krohmal B, Emanuel EJ, Grady C, Wendler D for the ESPRIT Study/Group.
J Empir Res Hum Res Ethics 2009; 4(3):89-97. abstract

2008

1 In vivo study of experimental pneumococcal meningitis using magnetic resonance imaging. CT Brandt, H Simonsen, M Liptrot, LV Sogaard, JD Lundgren, C Ostergaard, N Frimodt-Moller, IJ Rowland
BMC Med Imaging. 2008 Jan 14;8(1):1 [Epub ahead of print]. abstract

2 Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. WP Bannister, L Ruiz, A Cozzi-Lepri, A Mocroft, O Kirk, S Staszewski, C Loveday, A Karlsson, A Monforte, B Clotet, JD Lundgren; EuroSIDA Study Group
AIDS. 2008 Jan 30;22(3):367 abstract

3 The role of antiretroviral therapy on the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. CJ Smith, CH Olsen, A Mocroft, JP Viard, S Staszewski, G Panos, T Staub, A Balxhult, N Vetter, JD Lundgren for the EuroSIDA study group.
AIDS. 2008 Jan 2;22(1):47-56.abstract

4 Impact of bacteremia on the pathogenesis of experimental pneumococcal meningitis. CT Brandt, D Holm, M Liptrot, C Østergaard, JD Lundgren, N Frimodt-Møller, IC Skovsted and IJ Rowland.
J Infect Dis. 2008 Jan 15;197(2):235-244. abstract

5 Procalcetonin in liver transplant patients - yet another stone turned. JU Jensen and JD Lundgren.
Crit Care Med. 2008, Jan 22;12:108 abstract

6 Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. S de Wit, CA Sabin, R Weber, SW Worm, P Reiss, C Cazanave, W El-Sadr, A d´Arminio Monforte, E Fontas, MG Law, N Friis-Møller, JD Lundgren.
Diabetes Care. 2008 Feb 11 abstract

7 Regional differences in the risk of triple class failure in European patients starting cART after 1 January 1999. A Mocroft, A Horban, B Clotet, A d’Arminio Monforte, JR Bogner, P Aldins, T Staub, F Antunes, C Katlama, JD Lundgren for the EuroSIDA study group.
HIV Med. 2008 Jan;9(1):41-6. abstract

8 Loss to follow-up in an international, multicentre observational study. A Mocroft, O Kirk, P Aldins, A Chies, A Blaxhult, N Chentsova, N Vetter, F Dabis, J Gatell and JD Lundgren, for the EuroSIDA study group.
HIV Med. 2008 9(1):261-269 abstract

9 EACS Executive Committee.European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. JD Lundgren, M Battegay, G Behrens, S De Wit, G Guaraldi, C Katlama, E Martinez, D Nair, WG Powderly, P Reiss, J Sutinen, A Vigano;
HIV Med. 2008 Feb;9(2):72-81 abstract

10 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Writing group: CA Sabin, SW Worm, R Weber, P Reiss, W E l Sadr, F Dabis, S De Wit, M Law, A D´Arminio Monforte, N Friis-Møller, O Kirk, C Pradier, I Weller, AN Phillips, JD Lundgren.
Lancet. 2008 Apr 26;371(9622):1417-26. E pub 2008 Apr 2 abstract

11 Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. AN Phillips, D Pillay, AH Miners, DE Bennett, CF Gilks, JD Lundgren.
Lancet. 2008 Apr 26;371(9622):1443-51 abstract

12 Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. CJ Smith, A Mocroft, JD Lundgren; EuroSIDA Study Group.
AIDS. 2008 May 11;22(8):997-8. abstract

13 Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction. Data Collection on Adverse Events of Anti-HIV Drugs Study Group, CA Sabin, A d'Arminio Monforte, N Friis-Moller, R Weber, WM El-Sadr, P Reiss, O Kirk, P Mercie, MG Law, S De Wit, C Pradier, AN Phillips, JD Lundgren.
Clin Infect Dis. 2008 Apr 1;46(7):1101-10 abstract

14 Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, JD Lundgren, A Babiker, W El-Sadr, S Emery, B Grund, JD Neaton, J Neuhaus, AN Phillips.
J Infect Dis. 2008 Apr 15;197(8):1145-55 abstract

15 Determination of the underlying cause of death in three multicenter international HIV clinical trials. AR Lifson, WH Belloso, C Carey, RT Davey, D Duprez, WM El-Sadr, JM Gatell, DC Gey, JF HOy, EA KRum, R Nelson, DE Nixon, N Paton, C Pedersen, G Perez, RW PRice, RJ Prineas, FS Rhame, J Sampson, J Worley.
HIV Clin Trials 2008; 9:177-185 abstract

16 Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial. AN Phillips, A Carr, J Neuhaus, F Visnegarwala, R Prineas, WJ Burman, I Williams, F Drummond, D Duprez, WH Belloso, FD Goebel, B Grund, A Hatzakis, J Vera, JD Lundgren.
Antivir Ther. 2008;13(2):177-87 abstract

17 Transmitted drug resistance and association with virological and CD4 cell count response to combination antiretroviral therapy in EuroSIDA. WP Bannister, A Cozzi-Lepri, B Clotet, A Mocroft, J Kjær, P Reiss, V von Wyl, A Lazzarin, C Katlama, AN Phillips, L Ruiz, JD Lundgren and the EuroSIDA study group.
J Acquir Immune Defic Syndr. 2008 Jun 9. [Epub ahead of print] abstract

18 Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. K Deforche, A Cozzi-Lepri, K Theys, B Clotet, RJ Camacho, J Kjær, K Van Laethem, AN Phillips, Y Moreau, JD Lundgren, and A-M Vandamme on behalf of the EuroSID Study Group.
Antivir Ther. 13:399-407 abstract

19 State of the Science Conference. Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS Executive Summary. SK Grinspoon, C Grunfeld, DP Kotler, JS Currier, JD Lundgren, MP Dubé, SE Lipshultz, PY Hsue, K Squires, M Schambelan, PW Wilson, KE Yarasheski, CM Hadigan, JH Stein, RH Eckel.
Circulation. 2008 Jun 19. [Epub ahead of print] abstract

20 Epidemiological Evidence for Cardiovascular Disease in HIV-Infected Patients and Relationship to Highly Active Antiretroviral Therapy.JS Currier, JD Lundgren, A Carr, D Klein, CA Sabin, PE Sax, JT Schouten, M Smieja; for Working Group 2.
Circulation. 2008 Jun 19. [Epub ahead of print] abstract

21 Development of Appropriate Coronary Heart Disease Risk Prediction Models in HIV-Infected Patients. M Schambelan, PW Wilson, KE Yarasheski, WT Cade, VG Dávila-Román, RB Sr D'Agostino, TA Helmy, M Law, KE Mondy, S Nachman, LR Peterson, SW Worm; for Working Group 5.
Circulation. 2008 Jun 19. [Epub ahead of print] abstract

22 Prevention Strategies for Cardiovascular Disease in HIV-Infected Patients. JH Stein, CM Hadigan, TT Brown, E Chadwick, J Feinberg, N Friis-Møller, A Ganesan, MJ Glesby, D Hardy, RC Kaplan, P Kim, J Lo, E Martinez, JM Sosman; for Working Group 6.
Circulation. 2008 Jun 19. [Epub ahead of print]

23 Indicator disease-guided testing for HIV--the next step for Europe? B Gazzard, N Clumeck, A d'Arminio Monforte, JD Lundgren.
HIV Med. 2008 Jul;9 Suppl 2:34-40. abstract

24 Fungal infection as a risk factor for HIV disease progression among patients with a CD4 count above 200/microl in the era of cART. D Podlekareva, A Mocroft, O Kirk, P Reiss, P Aldins, C Katlama, H Kovari, HJ Stellbrink, A D'Arminio Monforte, JD Lundgren.
Scand J Infect Dis. 2008 Jun 18:1-6. [Epub ahead of print] abstract

25 Pneumonia in HIV-Infected Persons: Increased Risk with Cigarette Smoking and Treatment Interruption.. FM Gordin, MP Roediger, PM Girard, JD Lundgren, JM Miro, A Palfreeman, MC Rodriguez-Barradas, MJ Wolff, PJ Easterbrook, K Clezy, LN Slater.
Am J Respir Crit Care Med. 2008 Jul 10. [Epub ahead of print] abstract

26 The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. JU Jensen, B Lundgren, L Hein, T Mohr, PL Petersen, LH Andersen, AO Lauritsen, S Hougaard, T Mantoni, B Bømler, KJ Thornberg, K Thormar, J Løken, M Steensen, P Carl, JA Petersen, H Tousi, P Søe-Jensen, M Bestle, S Hestad, MH Andersen, P Fjeldborg, KM Larsen, C Rossau, CB Thomsen, C Ostergaard, J Kjaer, J Grarup, JD Lundgren.
BMC Infect Dis. 2008 Jul 13;8:91. abstract

27 Prediction of phenotypic susceptibility to antiretroviral drugs using physiochemical properties of the primary enzymatic structure combined with artificial neural networks. J Kjær, L Høj, Z Fox, JD Lundgren.
HIV Med. 2008 Jul 2. [Epub ahead of print] abstract

28 Optimal HIV testing and earlier care:the way forward in Europe. T Coenen, J Lundgren, J Lazarus, S Matic.
HIV Med. 2008 JUl;9 Suppl 2:1-5. abstract

29 Incidence of abacavir hypersensitivity reactions in EuroSIDA. WP Bannister, N Friis-Møller, A Mocroft, J-P Viard, J van Lunzen, O Kirk, P Gargalianos, D Bánhegyi, A Chiesi, JD Lundgren, and the EuroSIDA study group.
Antivir Ther. 2008;13(5):687-96 abstract

30 The clinical application of the EuroSIDA risk score. J Reekie, A Mocroft, O Kirk and J D Lundgren.
AIDS & Hepatitis digest. 2008; 126:1-5

31 Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. The SMART/INSIGHT and the D:A:D study groups. Writing committee: JD Lundgren, J Neuhaus, A Babiker, D Cooper, D Duprez, W El-Sadr, S Emery, F Gordin, J Kowalska, A Phillips, RJ Prineas, P Reiss, C Sabin, R Tracy, R Weber, B Grund and JD Neaton.
AIDS.2008, 22:F17-F24 abstract

32 Risk for opportunistic disease and death after reinitiating continous antiretroviral therapy in patients with HIV previously receiving episodic therapy. A randomized trial. The SMART study group. Writing group: WM El-Sadr, B Grund, J Neuhaus, A Babiker, CJ Cohen, J Darbyshire, S Emery, JD Lundgren, A Phillips and JD Neaton.
Ann Intern Med. 2008;149:289-299 abstract

33 HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. A Monforte, D Abrams, C Pradier, R Weber, P Reiss, F Bonnet, O Kirk, M Law, S De Wit, N Friis-Møller, AN Phillips, CA Sabin, JD Lundgren; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group.
AIDS. 2008 Oct 18;22(16):2143-53 abstract

34 The elusive search for an HIV vaccine-And what to do meanwhile. JV Lazarus, A Häggblom, L Kirkegaard, JD Lundgren, S Matic.
Vaccine. 2008 Sep 24. abstract

35 Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection. LH Kuller, R Tracy, W Belloso, SD Wit, F Drummond, HC Lane, B Ledergerber, J Lundgren, J Neuhaus, D Nixon, NI Paton, JD Neaton for the INSIGHT SMART Study Group.
PLoS Med. 2008 Oct 21;5(10):e203. abstract

36 The EuroSIDA study: regional differences in HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe - a review of published results. D Podlekareva, W Bannister, A Mocroft, L Abrosimova, I Karpov, JD Lundgren, O Kirk for the EuroSIDA study group
Cent Eur J Public Health. 2008 Sep;16(3):99-105.abstract

37 Detection of HIV drug resistance during antiretrovrial treatment and clinical progression in a large European cohort study. A Cozzi-Lepri, AN Phillips, B Clotet, A Mocroft, L Ruiz, O Kirk, A Lazzarin, A Wiercinska-Drapalo, A Karlsson, JD Lundgren for the EuroSIDA Study Group.
AIDS. 2008 Oct 18;22(16):2187-98. abstract

38 Cardiovascular risk in HIV Disease. Edited by JS Currier and JD Lundgren.
Curr. Opin in HIV & AIDS. 3(3):205-251, May 2008

39 Guidelines for managing cardiovascular risk: an evolving area. JS Currier, JD Lundgren
Curr. Opin in HIV & AIDS. 3(3):205-206, May 2008. abstract

40 Conventional cardiovascular risk factors in HIV Infection: how conventional are they? C Sabin, SW Worm
Curr. Opin in HIV & AIDS. 3(3):214-219, May 2008. abstract

41 Antiretroviral therapy as a cardiovascular disease risk factor: fact or fiction? A review of clinical and surrogate outcome studies. N Friis-Møller, M Smieja, D Klein
Curr. Opin in HIV & AIDS. 3(3):220-225, May 2008. abstract

42 EuroSIDA: a prospective observational study of chronic HIV Infection across the European Continent. JD Lundgren, O Kirk, A Mocroft
[Bookchapter from “A Decade og HAART”, published by Oxford University Press. p.195-212]

43 Response to combination antiretroviral therapy: variation by age. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study group.
AIDS. 22(12):1463-1473, July 31, 2008 abstract

44 The ART Cohort Collaboration: Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? Writing committee: Michael J. Mugavero, Margaret May, Ross Harris, Michael S. Saag, Dominique Costagliola, Matthias Egger, Andrew Phillips, Huldrych Günthard, Francois Dabis, Robert Hogg, Frank de Wolf, Gerd Fatkenheuer, John Gill, Amy Justice, Antonella D'Arminio Monforte, Fiona Lampe, Jose Maria Miró, Schlomo Staszewski , Mari Kitahata and Jonathan A C Sterne. AIDS 2008; 22: 2481-2492. abstract

45 The ART Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Writing committee: Hogg, R., Lima V., Sterne, J.A.C. Grabar, S., Battegay, M., Bonarek, M., D’Arminio Monforte, A., Esteve, A., Gill, M.J., Harris, R., Justice, A., Hayden, A., Lampe, F., Mocroft, A., Mugavero, M.J., Staszewski, S., Wasmuth J.C., van Sighem, A., Kitahata, .M, Guest, J., Egger, M. and May, M. Lancet 2008; 372: 293-299. abstract

46 The role of HIV in serious diseases other than AIDS. Phillips AN, Neaton J, Lundgren JD. AIDS. 2008 Nov 30;22(18):2409-18. Review. PubMed PMID: 19005264; PubMed Central PMCID: PMC2679976. abstract

47 Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure? Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren JD; EuroSIDA Study Group. AIDS. 2008 Nov 12;22(17):2381-90. PubMed PMID: 18981778. abstract

48 Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen. Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group. AIDS. 2008 Nov 12;22(17):2279-89. PubMed PMID: 18981767. abstract

49 Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh J, Klein MB, Dore GJ, Mocroft A, Soriano V, Clotet B, Lundgren JD; SMART Study Group and International Network for Strategic Initiatives in Global HIV Trials (INSIGHT). Clin Infect Dis. 2008 Dec 1;47(11):1468-75. PubMed PMID: 18959492. abstract

50 ART failure and strategies for switching ART regimens in Europe. Eramova I, Munz M, Lundgren J, Matic S. Cent Eur J Public Health. 2008 Sep;16(3):141-4. PubMed PMID: 18935782. abstract

51 Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J; EuroSIDA Study Group. J Infect Dis. 2008 Nov 1;198(9):1337-44. PubMed PMID: 18767985.  abstract

52 Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R. J Infect Dis. 2008 Apr 15;197(8):1133-44. PubMed PMID:18476292. abstract

53 Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy. Calmy A, Carey D, Mallon PW, Wand H, Law M, Cooper DA, Carr A; INITIO Trial International Co-ordinating Committee; HAMA study coordination team. HIV Med. 2008 Feb;9(2):101-10. PubMed PMID: 18257772. abstract

54 European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. Clumeck N, Pozniak A, Raffi F; EACS Executive Committee. HIV Med. 2008 Feb;9(2):65-71. PubMed PMID: 18257769. abstract

55 Antiretroviral Therapy Cohort Collaboration. Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies. Harris RJ, Sterne JA, Abgrall S, Dabis F, Reiss P, Saag M, Phillips AN, Chêne G, Gill JM, Justice AC, Rockstroh J, Sabin CA, Mocroft A, Bucher HC, Hogg RS, Monforte AD, May M, Egger M. Antivir Ther. 2008;13(8):959-67. PubMed PMID: 19195321. abstract

56 Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice? Antiretroviral Therapy Cohort Collaboration (ART-CC), Mugavero MJ, May M, Harris R, Saag MS, Costagliola D, Egger M, Phillips A, Günthard HF, Dabis F, Hogg R, de Wolf F, Fatkenheuer G, Gill MJ, Justice A, D'Arminio Monforte A, Lampe F,Miró JM, Staszewski S, Sterne JA. AIDS. 2008 Nov 30;22(18):2481-92. PubMed PMID:19005271. abstract

57 Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. Mussini C, Manzardo C, Johnson M, Monforte A, Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi V, Lazzarin A, Miró JM, Sabin C; Late Presenter Investigators. AIDS. 2008 Nov 30;22(18):2461-9. PubMed PMID: 19005269. abstract

58 The EuroSIDA study: Regional differences in the HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe--a review of published results. Podlekareva D, Bannister W, Mocroft A, Abrosimova L, Karpov I, Lundgren JD, Kirk O; EuroSIDA Study Group. Cent Eur J Public Health. 2008 Sep;16(3):99-105. Review. PubMed PMID: 18935770. abstract

59 Episodic antiretroviral therapy increases HIV transmission risk compared with continuous therapy: results of a randomized controlled trial. Burman W, Grund B, Neuhaus J, Douglas J Jr, Friedland G, Telzak E, Colebunders R, Paton N, Fisher M, Rietmeijer C for the SMART Study Group and INSIGHT.
J Acquir Immun Defic Synd 2008; 49:142-150. abstract

60 The impact of episodic CD4 cell count-guided antiretroviral therapy on qualify of life. Burman WJ, Grund B, Roediger MP, Friedland G, Darbyshire J, Wu AW for the SMART Study Group.
J Acquir Immun Defic Synd 2008; 47(2):185-193. abstract

61 Why patients continue to participate in clinical research. Wendler D, Krohmal B, Emanuel EJ, Grady C for the ESPRIT Group.
Arch Int Med 2008; 168(12):1294-1299.

2007

1 When should antiretroviral therapy for HIV be started? AN Phillips, BG Gazzard, N Clumeck, MH Losso, JD Lundgren. Editorial BMJ 2007;334;76-78 article

2 Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. C Holkmann Olsen, A Mocroft, O Kirk, S Vella, A Blaxhult, N Clumeck, M Fisher, C Katlama, AN Phillips and JD Lundgren for the EuroSIDA study group.
HIV Med. 2007;8;96-104 abstract

3 Class of Antiretroviral Drugs and the Risk of Myocardial Infarction. Writing committee: N Friis-Møller, P Reiss, CA Sabin, R Weber, A D´Arminio Monforte, W El-Sadr, R Thiebaut, S de Wit, O Kirk, E Fontas, MG Law, A Phillips, JD Lundgren on behalf of the D:A:D study group.
N Engl J Med. 2007 April 26;356:1723-35 abstract

4 Evolution of drug resistance in HIV infected patients remaining on a virologically failing cART regimen. A Cozzi-Lepri, AN Phillips, L Ruiz, B Clotet, C Loveday, J Kjær, H Mens, N Clumeck, L Viksna, F Antunes, L Machala, JD Lundgren.
AIDS. 2007 Mar 30;21(6):731-32 abstract

5 Chronic renal failure among HIV-1-infected patients. A Mocroft, O Kirk, J Gatell, P Reiss, P Gargalianos, K Zilmer, M Beniowski, J-P Viard, S Staszewski, and JD Lundgren for the EuroSIDA study group.
AIDS. 2007 May 31, 21(9):1119-1127 abstract

6 Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. The Antiretroviral Therapy (ART) Cohort Collaboration. Writing committee:M May, JAC Sterne, C Sabin, D Costagliola, AC Justice, R Thiebaut, J Gil, A Phillips, P Reiss, R Hogg, B Ledergerber, A D´arminio Monforte, N Schmeisser, S Staszewski, M Egger.
AIDS. 2007 May 31, 21(9):1185-1197 abstract

7 Primary Pneumocystis infection in infants hospitalized with acute respiratory tract infection. H Larsen, M-L von Linstow, B Lundgren, B Hogh, H Westh, JD Lundgren.
Emerg Infect Dis. 2007 Jan;13(1):66-72 abstract

8 Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2. The ESPRIT Research Group; Z Fox, F Antunes, R Davey, B Gazzard, N Klimas, A Labriola, M Losso, JD Neaton, AN Phillips, K Ruxrungtham, S Staszewski, L Weiss, JD Lundgren.
HIV Med. 2007 Mar;8(2):112-23 abstract

9 Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. A Mocroft, AN Phillips, J Gatell, B Ledergerber, M Fisher, N Clumeck, M Losso, A Lazzarin, JD Lundgren for the EuroSIDA study group.
Lancet. 2007 July 19, online. Lancet. 2007 Aug 4;370(9585):407-13 abstract

10 A coronary heart disease risk model for predicting the effect of potent antiretroviral therapy in HIV-1 infected men. M May, JAC Sterne, M Shipley, E Brunner, R d'Agostino, P Whincup, Y Ben-Shlomo, A Carr, B Ledergerber, JD Lundgren, AN Phillips, J Massaro, M Egger.
Int J Epidemiol. 2007, 25 July, online; doi:10.1093/ije/dym135 abstract

11 Short term clinical disease progression in HIV-1 positive patients taking combination antiretroviral therapy : The EuroSIDA risk-score. A Mocroft, B Ledergerber, K Zilmer, O Kirk, JP Viard, P Reiss, A Lazzarin, L Machala, AN Phillips, JD Lundgren for the EuroSIDA study group.
AIDS. 2007 Sep;21(14):1867-1875. abstract

12 Risk of discontinuation of nevirapine due to toxicities in antiretroviral naive and experienced HIV-infected patients with high and low CD4 counts. A Mocroft, S Staszewski, R Weber, J Gatell, J Rockstroh, J Gasiorowski, G Panos, A d’Arminio Monforte, A Rakhmanova, AN Phillips, JD Lundgren
Antivir Ther. 2007;12(3):325-33. Erratum in: Antivir Ther. 2007;12(4):577 abstract

13 Current haemoglobin levels are more predictive of disease progression than haemoglobin measured at baseline in patients receiving antiretroviral tratment for HIV-1 infection. JD Kowalska, A Mocroft, A Blaxhult, R Colebunders, J van Lunzen, D Podlekareva, A-BE Hansen, L Machala, I Yust and T Benfield for the EuroSIDA Study Group.
AIDS Res Hum Ret. 2007; 23 (10): 1183-1188 abstract

14 Clinical outcomes in clinical trials of anti-HIV treatment. J Reekie, A Mocroft, J Neaton and JD Lundgren.
Future HIV Ther. 2007 1(3), 251-258 abstract

15 Risk of cancers during interrupted antiretroviral therapy in the SMART study. MJ Silverberg, J Neuhaus, M Bower, D Gey, A Hatzakis, K Henry, J Hidalgo, L Lourtau, JD Neaton, G Tambussi, and DI Abrams.
AIDS. 2007, 21:1957-1963 abstract

16 Meta-analysis of procalcitonin for sepsis detection. JU Jensen, B Lundgren, JD Lundgren.
Lancet Infect Dis. 2007 Aug; 7(8):499-500 abstract

17 Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue based regimens in ART-naïve and experienced patients. F Ceccherini-Silberstein, A Cozzi-Lepri, L Ruiz, A Mocroft, AN Phillips, C Holkmann-Olsen, JM Gatell, FH Günthard, P Reiss, CF Perno, B Clotet, and JD Lundgren for the EuroSIDA study group.
J Infect Dis. 2007 Oct 15;196(8):1180-90. Epub 2007 Sep 19. abstract

18 Pharmacokinetics from two randomised trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose rintonavir: The MaxCmin 1 & 2 Trials.
US Justesen, Z Fox, C Pedersen, P Cahn, J Gerstoft, N Clumeck, M Losso, B Peters, N Obel, A Castagna, UB Dragsted, and JD Lundgren on behalf of the MaxCmin 1 & 2 Trial groups.
Basic Clin Pharmacol Toxicol. 2007 Nov;101(5):339-44. abstract

19 Can the Risk of Cardiovascular Disease in HIV Infected Patients be Estimated From Conventional Risk Prediction Tools? N Friis-Møller, and SW Worm. Commentary.
Clin Infect Dis. 2007 Oct 15;45(8):1082-4. Epub 2007 Sep 12. commentary

 

20 The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. ZV Fox, AM Geretti, J Kjaer, UB Dragsted, AN Phillips, J Gerstoft, S Staszewski, B Clotet, V von Wyl, JD Lundgren.
AIDS. 2007 Oct 1;21(15):2033-42. abstract

21 HIV in the UK 1980-2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy. AN Phillips, C Sabin, D Pillay, JD Lundgren.
HIV Med. 2007 Nov;8(8):536-46. abstract

22 Dynamic use of procalcitonin in the intensive care unit. JU Jensen, L Hein, K Thornberg, J Loeken, H Tousi, KM Larsen, MH Andersen, M Bestle, T Mohr.
Int J Intensive Care. 2007;14(2):52-57

23 The Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA) and The ART Cohort Collaboration: Tuberculosis after Initiation of Antiretroviral Therapy in Low-Income and High-Income Countries. CID 2007;45:1518–1521.

24 The ART Cohort Collaboration: Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1 Infected Patients. Writing committee: Jonathan A C Sterne, Margaret May, Caroline Sabin, Andrew Phillips, Dominique Costagliola, Geneviève Chêne, Amy C Justice, Frank de Wolf, Robert Hogg, Manuel Battegay, Antonella D’Arminio Monforte, Norbert Schmeisser, Schlomo Staszewski, John Gill and Matthias Egger. J Acquir Immune Defic Syndr 2007; 46:607–615.

25 HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. Sterne JA, May M, Bucher HC, Ledergerber B, Furrer H, Cavassini M, Bernasconi E, Hirschel B, Egger M; Swiss HIV Cohort. J Intern Med 2007 261:255-67. abstract

26 Visceral and subcutaneous adiposity measurements in adults: Influence of measurement site. Ellis KJ, Grund B, Visnegarwala F, Thackeray L, Miller CG, Chesson CE, El-Sadr W, and Carr A for the Strategies for Management of Anti-Retroviral Therapy (SMART) Study Group.
Obesity 2007; 15(6):1441-1447. abstract

2006

1 The Use of the Framingham Equation to Predict Myocardial Infarctions in HIV-infected Patients: Comparison with Observed Events in the D:A:D Study.

MG Law, N Friis-Møller, WM El-Sadr, R Weber, P Reiss, A D'Arminio Monforte, R Thiébaut, L Morfeldt, S De Wit, C Pradier, G Calvo, O Kirk, CA Sabin, AN Phillips, and JD Lundgren for the D:A:D Study Group.
HIV Med. 2006;7;218-230 abstract

2 Relationship between antiretrovirals used as part of a cART regimen and CD4 count increases in patients with suppressed viremia. A Mocroft, A Phillips, B Ledergerber, C Katlama, A Chiesi F Goebel, B Knysz, F Antunes, P Reiss, J Lundgren for the EuroSIDA study group.
AIDS. 2006 May 12;20(8):1141-1150 abstract

3 The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. A Mocroft, J Neaton, J Bebchuk, S Staszewski, F Antunes, B Knysz, M Law, AN Phillips, J Lundgren for the EuroSIDA and ESPRIT study groups.
Clin Trials. 2006 May;3(2):119-132 abstract

4 Regional changes over time in initial virological response rates to combination antiretroviral therapy across Europe. W Bannister, O Kirk, J Gatell, B Knysz, J-P Viard, H Mens, A D'Arminio Monforte, A Phillips, A Mocroft, J Lundgren for the EuroSIDA study group.
J Acquir Immune Defic Syndr. 2006 Jun;42(2):229-237 abstract

5 Liver-related deaths among persons infected with the human immunodeficiency virus: The D:A:D Study. Writing committee: R Weber, CA Sabin, N Friis-Møller, P Reiss, WM. El-Sadr, O Kirk, F Dabis, MG Law, C Pradier, S De Wit, B Åkerlund, G Calvo, A d’Arminio Monforte, M Rickenbach, B Ledergerber, AN Phillips, and JD Lundgren
Arch Intern Med. 2006;166:1632-1641 abstract

6 Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial. Writing committee: P Yeni, DA Cooper, J-P Aboulker, AG Babiker D Carey, JH Darbyshire, M Floridia, P-M Girard, RL Goodall, MH Hooker, A Mijch, V Meiffredy, B Salzberger for the INITIO trial coordinating committee.
Lancet. 2006; 368:287-98 abstract

7 Factors associated with development of opportunistic infections in HIV-1 infected adults with high CD4 cell counts: a EuroSIDA study. D Podlekareva, A Mocroft, UB Dragsted, B Ledergerber, M Beniowski, A Lazzarin, J Weber, N Clumeck, N Vetter, A Phillips, and JD Lundgren for the EuroSIDA study group
J Infect Dis. 2006 Sep 1; 194(5):633-41 abstract

8 Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis. M Puoti, A Cozzi-Lepri, C Arici C, NF Moller, JD Lundgren, B Ledergerber, M Rickenbach, I Suarez-Lozano, M Garrido, F Dabis, M Winnock, L Milazzo, A Gervais, F Raffi, J Gill, J Rockstroh, N Ourishi, C Mussini, A Castagna, A De Luca, A Monforte; HBV-HIV International Intercohort Study Group.
Antivir Ther. 2006;11(5):567-74 abstract

9 Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. A Lifson, FS Rahme, WH Belloso, UB Dragsted, WM El-Sadr, JM Gatell, JF Hoy, EA Krum, R Nelson, C Pedersen, SL Pett, RT Davey for the ESPRIT and SILCAAT Research Groups.
HIV Clin Trials. 2006;7(3):125-141 abstract

10 HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. M May, J Sterne, D Costagliola, M Egger, C Sabin, A Phillips, A Justice, F Dabis, J Gill, J Lundgren, R Hogg, F de Wolf, G Fätkenheuer, S Staszewski, and A d´Arminio Monforte for The Antiretroviral Therapy (ART) Cohort Collaboration.
Lancet. 2006 Aug 5;368(9534):451-8 abstract

11 HIV-1 subtypes and response to combination antiretroviral therapy in Europe. WP Bannister, L Ruiz, C Loveday, S Vella, K Zilmer, J Kjær, B Knysz, AN Phillips, A Mocroft, JD Lundgren for the EuroSIDA study group
Antiviral Therapy 2006; 11: 707-715 abstact

12 A randomized trial to evaluate continuation versus discontinuation fo lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial. Z Fox, UB Dragsted, J Gerstoft, AN Phillips, J Kjaer, L Mathiesen, M Youle, C Katlama, A Hill, JN Bruun, N Clumeck, P Dellamonica and JD Lundgren on behalf of the The COLATE study group
Antiviral Therapy 2006; 11: 761-770 abstract

13 CD4+ Count-Guided Interruption of Antiretroviral Treatment. The Strategies for Mangement of Antiretroviral Therapy (SMART) Study Group. Writing Group: WM El-Sadr, JD Lundgren, JD Neaton, F Gordin, D Abrams, RC Arduino, A Babiker, W Burman, N Clumeck, CJ Cohen, D Cohn, D Cooper, S Emery, G Fätkenheuer, B Gazzard, B Grund, J Hoy, K Klingman, M Losso, N Markowitz, J Neuhaus, AN Phillips, and C Rappoport.
N Engl J Med 2006; 355(22); 2283-2296 abstract

14 The impact of antiretroviral therapy on AIDS and survival. JD Lundgren, A Mocroft
J HIV Ther.2006 Jun;11(2):36-8 abstract article

15 Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. A Mocroft, J Rockstroh, V Soriano, O Kirk, J-P Viard, S Caplinskas, J Gasiorowski, A Chiesi, AN Phillips, JD Lundgren for the EuroSIDA Study.
Scand J Inf Dis. 2006;38:1092-1097 abstract

16 Hearing loss and cochlear damage in experimental pneumococcal meningitis, with special reference to the role of neutrophil granulytes. CT Brandt, P Caye-Thomsen, SP Lund, L Worsøe, C Østergaard, N Frimodt-Møller, F Espersen, J Thomsen, JD Lundgren.
Neurobiol Dis. 2006 Aug;23(2):300-11 abstract

17 Evaluation of anti-pneumococcal capsular antibodies as adjunctive therapy in experimental pneumococcal meningitis. CT Brandt, N Frimodt-Moller, JD Lundgren, M Pedersen, IC Skovsted, IJ Rowland, C Ostergaard.
J Antimicrob Chemother. 2006 Dec;58(6):1291-4 abstract

18 Influence of the blood bacterial load on the meningeal inflammatory response in Streptococcus pneumoniae meningitis. C Ostergaard, T O'Reilly, C Brandt, N Frimodt-Moller, JD Lundgren.
BMC Infect Dis. 2006 Apr 27;6:78 article

19 Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000. A Mocroft, A Horban, N Clumeck, HJ Stellbrink, A d´Arminio Monforte, K Zilmer, O Kirk, J Gatell, AN Phillips, and JD Lundgren for the EuroSIDA study group.
HIV Clin Trials. 2006;7(6):271-284 article

20 The CD4 lymphocyte count and risk of clinical progression. AN Phillips and JD Lundgren
Curr. Opin. in HIV&AIDS. 2006 Jan; 1(1):43-49 abstract

21 Procalcitonin increase in early identification of critically ill patients at high risk of mortality. JU Jensen, L Heslet, TH Jensen, K Espersen, P Steffensen, M Tvede.
Crit Care Med. 2006 Oct;34(10):2596-602 article

22 The ART Cohort Collaboration. Rates of disease progression according to initial HAART regimen: A collaborative analysis of 12 prospective cohort studies. Writing committee: Robert Hogg, Margaret May, Andrew Phillips, Dominique Costagliola, Jonathan Sterne, Caroline Sabin, Frank De Wolf, Bruno Ledergerber, Antonella D'Arminio Monforte, Amy Justice, John Gill, Gregory Fusco, Schlomo Staszewski, Jurgen Rockstroh, Geneviève Chêne and Matthias Egger. Journal of Infectious Diseases 2006 194: 612-622 article

23  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration and the ART Cohort Collaboration Braitstein P, Brinkhof MWG, Dabis F, Schechter M, Boulle A, Miotti P, Wood R, Laurent C, Sprinz E, Seyler C, Bangsberg D, Balestre E, Sterne J, May M, Egger M. Lancet 2006 367: 817-824. article